• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗血友病因子并非所有VIII因子缺乏症的唯一解决方案。一名甲型血友病患者发生牙源性感染的病例报告，该患者并发VIII因子抑制剂，并通过输注抗血友病因子和VIII因子抑制剂旁路活性进行治疗。

"Antihemophilic factor is not the only answer for all factor VIII deficiencies." Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity.

作者信息

Sudheesh K M, Bharani K S N Siva, Kiran H Y, Hanagavadi Suresh

机构信息

Department of Oral and Maxillofacial Surgery, College of Dental Sciences, Davangere, Karnataka, India.

Department of Pathology, J J M Medical College, Davangere, Karnataka, India.

出版信息

Indian J Dent. 2016 Sep;7(3):149-152. doi: 10.4103/0975-962X.186700.

DOI:10.4103/0975-962X.186700
PMID:27795652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5015568/
Abstract

Dental extraction in hemophiliacs with acquired inhibitors is always a risky procedure, which often presents a lot of problems associated with bleeding. A known case of hemophilia A complicated with factor VIII inhibitors and having odontogenic infection was successfully managed by transfusion of factor VIII inhibitor bypass activity (FEIBA) and antihemophilic factor. Past medical history was significant for multiple factor VIII transfusions. Bethesda assay done to identify inhibitors revealed low titer factor VIII inhibitors. Extraction of the involved tooth was done after transfusion of FEIBA with low-dose protocols. Minimal bleeding was noted after extraction which was controlled by local measures. FEIBA was proven to be highly effective, and no side effects of the product were observed.

摘要

患有获得性抑制剂的血友病患者进行拔牙始终是一项有风险的操作，常常会出现许多与出血相关的问题。一名已知的甲型血友病合并因子VIII抑制剂且患有牙源性感染的病例，通过输注因子VIII抑制剂旁路活性制剂（FEIBA）和抗血友病因子成功得到治疗。既往病史显示有多次输注因子VIII的情况。为确定抑制剂而进行的贝塞斯达检测显示因子VIII抑制剂滴度较低。在按照低剂量方案输注FEIBA后拔除了患牙。拔牙后出血极少，通过局部措施得以控制。事实证明FEIBA非常有效，且未观察到该产品的副作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/ecc8625e4ba0/IJDENT-7-149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/e87797cade8d/IJDENT-7-149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/c401219b44c7/IJDENT-7-149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/a479bf48dbc1/IJDENT-7-149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/9544c8613c21/IJDENT-7-149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/ecc8625e4ba0/IJDENT-7-149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/e87797cade8d/IJDENT-7-149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/c401219b44c7/IJDENT-7-149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/a479bf48dbc1/IJDENT-7-149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/9544c8613c21/IJDENT-7-149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d712/5015568/ecc8625e4ba0/IJDENT-7-149-g005.jpg

相似文献

1
"Antihemophilic factor is not the only answer for all factor VIII deficiencies." Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity.抗血友病因子并非所有VIII因子缺乏症的唯一解决方案。一名甲型血友病患者发生牙源性感染的病例报告，该患者并发VIII因子抑制剂，并通过输注抗血友病因子和VIII因子抑制剂旁路活性进行治疗。
Indian J Dent. 2016 Sep;7(3):149-152. doi: 10.4103/0975-962X.186700.
2
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.法国FEIBA在伴有凝血因子VIII和IX抑制剂患者中的应用多中心回顾性研究。法国FEIBA研究组。凝血因子VIII旁路活性。
Thromb Haemost. 1997 Jun;77(6):1113-9.
3
Management of Odontogenic Fascial Space Infection in Hemophilia Patients: A Proposed Protocol.血友病患者牙源性筋膜间隙感染的管理：一项拟议方案。
J Maxillofac Oral Surg. 2019 Jun;18(2):197-202. doi: 10.1007/s12663-018-1117-0. Epub 2018 May 9.
4
Inhibitor antibodies to factor VIII and factor IX: management.针对凝血因子VIII和凝血因子IX的抑制性抗体：管理
Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821.
5
Successful peritoneal dialysis in a hemophilia A patient with factor VIII inhibitor.血友病 A 伴 VIII 因子抑制物患者行腹膜透析成功。
Perit Dial Int. 2010 Jan-Feb;30(1):114-6. doi: 10.3747/pdi.2009.00011.
6
Antihemophilic factor (factor VIII).
Ann Intern Med. 1978 Mar;88(3):403-9. doi: 10.7326/0003-4819-88-3-403.
7
Acquired Hemophilia A After Multiple Transfusions Following Trauma.创伤后多次输血后获得性甲型血友病
Cureus. 2023 Dec 10;15(12):e50295. doi: 10.7759/cureus.50295. eCollection 2023 Dec.
8
[Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].[重组活化凝血因子VII（诺和七，诺和诺德公司）用于获得性凝血因子VIII抑制物血友病的止血治疗]
Schweiz Med Wochenschr. 1995 Mar 4;125(9):405-11.
9
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.人重组DNA衍生的抗血友病因子（凝血因子VIII）用于治疗甲型血友病。
Zhonghua Yi Xue Za Zhi (Taipei). 1999 Jul;62(7):450-4.
10
Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
Acta Haematol. 1980;64(1):12-7. doi: 10.1159/000207204.

引用本文的文献

1
Management of Odontogenic Fascial Space Infection in Hemophilia Patients: A Proposed Protocol.血友病患者牙源性筋膜间隙感染的管理：一项拟议方案。
J Maxillofac Oral Surg. 2019 Jun;18(2):197-202. doi: 10.1007/s12663-018-1117-0. Epub 2018 May 9.

本文引用的文献

1
Guidance on the dental management of patients with haemophilia and congenital bleeding disorders.血友病和先天性出血性疾病患者的牙科治疗指南。
Br Dent J. 2013 Nov;215(10):497-504. doi: 10.1038/sj.bdj.2013.1097.
2
Bleeding disorders of importance in dental care and related patient management.在牙科护理及相关患者管理中具有重要意义的出血性疾病。
J Can Dent Assoc. 2007 Feb;73(1):77-83.
3
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.凝血因子VIII和IX抑制物的诊断与管理：英国血友病中心医生组织指南
Br J Haematol. 2006 Jun;133(6):591-605. doi: 10.1111/j.1365-2141.2006.06087.x.
4
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.重组凝血因子VIIa与凝血因子VIII抑制剂旁路活性输注后的血栓形成事件发生率比较
J Thromb Haemost. 2004 Oct;2(10):1700-8. doi: 10.1111/j.1538-7836.2004.00944.x.
5
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.重组凝血因子VIII用于治疗既往未接受治疗的甲型血友病患者。安全性、有效性及抑制物的产生。科跃奇既往未治疗患者研究组。
N Engl J Med. 1993 Feb 18;328(7):453-9. doi: 10.1056/NEJM199302183280701.
6
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.重组因子VIII（重组凝血因子VIII）的多中心研究：既往未经治疗的甲型血友病患者的安全性、疗效及产生抑制剂的风险。重组凝血因子VIII研究组
Blood. 1994 May 1;83(9):2428-35.
7
The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.使用凝血因子 VIII 抑制物旁路活性制剂（FEIBA免疫）产品治疗有抑制物的血友病患者的出血发作。
Blood. 1983 Jan;61(1):36-40.
8
Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide.通过因子IX和环磷酰胺抑制B型血友病中的因子IX抗体。
Ann Intern Med. 1973 Jan;78(1):91-5. doi: 10.7326/0003-4819-78-1-91.
9
Factor VIII inhibitors. Etiology, characterization, natural history, and management.凝血因子 VIII 抑制剂。病因、特征、自然病程及管理
Ann N Y Acad Sci. 1987;509:89-102. doi: 10.1111/j.1749-6632.1987.tb30987.x.
10
Treatment of factor VIII inhibitors.
Prog Hemost Thromb. 1989;9:57-86.